631-645 of 930

Family Matters: The Link Between Family History & BRCA Mutations
Clinician's RoundtableFamily Matters: The Link Between Family History & BRCA Mutations

Genetic Testing for Hereditary Breast & Ovarian Cancers: What the Guidelines Say
Clinician's RoundtableGenetic Testing for Hereditary Breast & Ovarian Cancers: What the Guidelines Say

Expert Tips on Treating Genitourinary Syndrome of Menopause
SexMedExpert Tips on Treating Genitourinary Syndrome of Menopause

Reinventing Autologous Breast Reconstruction to Reduce Pain & Postsurgical Opioid Use
Medical Breakthroughs from Penn MedicineReinventing Autologous Breast Reconstruction to Reduce Pain & Postsurgical Opioid Use

Changing the Conversation in Palliative & Hospice Care
Primary Care TodayChanging the Conversation in Palliative & Hospice Care

Raising Awareness of Sickle Cell Disease
Everyday Family MedicineRaising Awareness of Sickle Cell Disease
- advertisement

What to Know About a State-of-the-Art Approach to GIST Treatment
Medical Breakthroughs from Penn MedicineWhat to Know About a State-of-the-Art Approach to GIST Treatment

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Project Oncology®FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
Medical Breakthroughs from Penn MedicineCAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer

Rethinking Nicotine: The Campaign to Break the World's Tobacco Habit
Primary Care TodayRethinking Nicotine: The Campaign to Break the World's Tobacco Habit

FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
FDA Drug Information UpdatesFDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
- advertisement

Pancreatic Cancer: The Hunt to Catch a Silent Killer
Project Oncology®Pancreatic Cancer: The Hunt to Catch a Silent Killer

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Project Oncology®FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
Project Oncology®FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer































